Avalo Therapeutics, Inc. Common Stock (NASDAQ: AVTX) last traded at $12.01, down 9.29% on the session. The quote above updates while this page is open; the figures below are drawn from Avalo Therapeutics, Inc. Common Stock’s own filings and are restated only when a new one is published.
Avalo Therapeutics, Inc. Common Stock trades on NASDAQ under the ticker AVTX. Its market capitalisation is $644.10 million.
Valuation measures for Avalo Therapeutics, Inc. Common Stock, derived from the latest quote and its most recent SEC filing.
| Market cap | $644.10M |
|---|---|
| Enterprise value | $600.84M |
| Price / sales | 10916.88 |
| Price / book | 1.44 |
| Beta | 1.13 |
Trailing-twelve-month figures tagged in Avalo Therapeutics, Inc. Common Stock's XBRL filings with the SEC.
| Revenue (TTM) | $59.0K |
|---|---|
| Net income (TTM) | -$100.33M |
| Operating margin | -154844.07% |
| Return on equity | -22.36% |
| Cash | $85.38M |
Range and volume for AVTX over the past 52 weeks.
| 52-week high | $24.27 |
|---|---|
| 52-week low | $11.99 |
| Volume | 1.65M |
| Average volume | 919.7K |
| Previous close | $13.24 |
Invest a chosen dollar amount in Avalo Therapeutics, Inc. Common Stock with fractional shares.
Start investingCreate an account
Investing involves risk, including possible loss of principal. Nothing here is investment advice or a recommendation to buy or sell AVTX.
A dash means FurlPay does not have that figure, not that it is zero. Nothing on this page is investment advice or a recommendation to buy or sell any security. Figures are provided for information only and may be delayed or restated.